Arax Advisory Partners Sells 3,502 Shares of Stryker Corporation $SYK

Arax Advisory Partners trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 43.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 4,512 shares of the medical technology company’s stock after selling 3,502 shares during the quarter. Arax Advisory Partners’ holdings in Stryker were worth $1,586,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC raised its stake in shares of Stryker by 25.8% in the 4th quarter. Barclays PLC now owns 1,168,656 shares of the medical technology company’s stock valued at $410,748,000 after purchasing an additional 239,650 shares during the period. Aigen Investment Management LP raised its stake in shares of Stryker by 188.2% in the 4th quarter. Aigen Investment Management LP now owns 3,375 shares of the medical technology company’s stock valued at $1,186,000 after purchasing an additional 2,204 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Stryker by 1,925.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 454,965 shares of the medical technology company’s stock valued at $159,907,000 after purchasing an additional 432,498 shares during the period. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the 4th quarter valued at about $27,000. Finally, Burton Enright Welch acquired a new stake in shares of Stryker in the fourth quarter valued at about $607,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. Barclays lowered their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Weiss Ratings downgraded Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Finally, Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Trading Down 1.4%

Stryker stock opened at $307.86 on Tuesday. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a market capitalization of $118.02 billion, a P/E ratio of 35.63, a PEG ratio of 1.97 and a beta of 0.78. The stock has a 50-day simple moving average of $315.93 and a 200 day simple moving average of $343.32.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.